Use of tumor necrosis factor α inhibitors in hepatitis B surface antigen-positive patients: A literature review and potential mechanisms of action

Clinical Rheumatology

Volumn 29, Issue 9, 2010, Pages 1021-1029

  Carroll, Matthew B ^a   Forgione, Michael A ^a  

^a KEESLER MEDICAL CENTER   (United States)

Author keywords

Ankylosing spondylitis; Crohn's disease; Hepatitis B virus; Psoriasis; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DRUG MECHANISM; DRUG POTENCY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER BIOPSY; MALE; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; VIRUS LOAD; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956189825     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1523-2     Document Type: Article

References (86)

1. JT Giles JM Bathon 2004 Serious infections associated with anticytokine therapies in the rheumatic diseases J Intensive Care Med 19 320 334 10.1177/0885066604267854 15523118
2. J Keane S Gershon RP Wise, et al. 2001 Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent N Engl J Med 345 1098 1103 10.1056/NEJMoa011110 11596589
3. JL Dienstag 2008 Hepatitis B virus infection N Engl J Med 359 14 1486 1500 10.1056/NEJMra0801644 18832247
4. MJ Shale CH Seow CS Coffin, et al. 2009 Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease Aliment Pharmacol Ther 31 20 34 10.1111/j.1365-2036.2009.04112.x
5. U.S. Food and Drug Administration Center for Drug Evaluation and Research (2008) Drugs@FDA: Adalimumab Label Information. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2008/125057s114lbl.pdf. Accessed 8 August 2009
6. U.S. Food and Drug Administration Center for Drug Evaluation and Research (2008) Drugs@FDA: Certolizumab Label Information. http://www.accessdata.fda. gov/drugsatfda-docs/label/2008/125160s000lbl.pdf. Accessed 8 August 2009
7. U.S. Food and Drug Administration Center for Drug Evaluation and Research (2008) Drugs@FDA: Etanercept Label Information. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2008/103795s5359lbl.pdf. Accessed 8 August 2009
8. U.S. Food and Drug Administration Center for Drug Evaluation and Research (2009) Drugs@FDA: Golimumab Label Information. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/125289s000lbl.pdf. Accessed 8 August 2009
9. U.S. Food and Drug Administration Center for Drug Evaluation and Research (2009) Drugs@FDA: Infliximab Label Information. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/103772s5234lbl.pdf. Accessed 8 August 2009
10. D Wendling V Di Martino C Prati, et al. 2009 Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy Jt Bone Spine 76 308 311 10.1016/j.jbspin.2008.11.005
11. D Wendling B Auge D Bettinger, et al. 2005 Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy Ann Rheum Dis 64 788 789 10.1136/ard.2004.031187 15834064
12. M Esteve C Loras F González-Huix 2007 Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient Inflamm Bowel Dis 13 11 1450 1451 10.1002/ibd.20202 17712837
13. M Esteve C Saro F González-Huix, et al. 2004 Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis Gut 53 1363 1365 10.1136/gut.2004.040675 15306601
14. S Zingarelli M Frassi C Bazzani, et al. 2009 Use of tumor necrosis factor-α-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature J Rheumatol 36 6 1188 1194 10.3899/jrheum.081246 19447932
15. S Zingarelli P Airò M Frassi, et al. 2008 Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases Reumatismo 60 1 22 27 18432322
16. CH Roux O Brocq V Breuil, et al. 2006 Safety of anti-TNF-α therapy in rheumatoid arthritis and spondyloarthropathies with concurrent B or C chronic hepatitis Rheumatology 45 1294 1297 10.1093/rheumatology/kel123 16603583
17. DU Cansu T Kalifoglu C Korkmaz 2008 Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis J Rheumatol 35 421 424 18203328
18. MB Carroll MI Bond 2008 Use of tumor necrosis factor-α inhibitors in patients with chronic hepatitis B infection Semin Arthritis Rheum 38 3 208 217 10.1016/j.semarthrit.2007.10.011 18221983
19. S Li PP Kaur V Chan 2009 Use of tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients Clin Rheumatol 28 787 791 10.1007/s10067-009-1149-4 19291350
20. PP Kaur VC Chan SN Berney 2008 Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports Clin Rheumatol 27 1069 1071 10.1007/s10067-008-0896-y 18521652
21. G Millonig M Kern O Ludwiczek, et al. 2006 Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 12 974 976 16521231
22. M Michel C Duvoux C Hezode, et al. 2003 Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease J Rheumatol 30 1624 1625 12858469
23. P Ostuni C Botsios L Punzi, et al. 2003 Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate Ann Rheum Dis 62 686 687 10.1136/ard.62.7.686 12810441
24. O Oniankitan C Duvous D Challine, et al. 2004 Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C J Rheumatol 31 107 109 14705228
25. Y Ueno S Tanaka M Shimamoto, et al. 2005 Infliximab Therapy for Crohn's disease in patient with chronic hepatitis B Dig Dis Sci 50 163 166 10.1007/s10620-005-1295-8 15712655
26. MG Anelli DD Torres C Manno, et al. 2005 Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab Arthritis Rheum 52 2519 2520 10.1002/art.21216 16052569
27. G-S MdV F Gomez-Camacho A Poyato-Gonzalez, et al. 2004 Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection Inflamm Bowel Dis 10 5 701 702 10.1097/00054725-200409000-00035
28. S Madonia A Orlando D Scimeca, et al. 2007 Occult hepatitis B and infliximab-induced HBV reactivation Inflamm Bowel Dis 13 4 508 10.1002/ibd.20035 17206687
29. H Robinson K Walker-Bone 2009 Anti-TNF-α therapy for rheumatoid arthritis among patients with chronic hepatitis B infection Rheumatology 48 450 451 10.1093/rheumatology/kep003
30. GT Sakellariou I Chatzigiannis 2007 Long-term anti-TNFα therapy for ankylosing spondylitis in two patients with chronic HBV infection Clin Rheumatol 26 950 952 10.1007/s10067-006-0392-1 16865308
31. C Colbert A Chavarria C Berkelhammer 2007 Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease Inflamm Bowel Dis 13 1453 1454 10.1002/ibd.20216 17600380
32. K Ojiro M Naganuma H Ebinuma, et al. 2008 Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab J Gastroenterol 43 397 401 10.1007/s00535-008-2165-x 18592158
33. LH Calabrese NN Zein D Vassilopoulos 2006 Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies Ann Rheum Dis 65 983 989 10.1136/ard.2005.043257 16627542
34. B Rehermann 2000 Intrahepatic T cells in hepatitis B: viral control versus liver cell injury J Exp Med 191 1263 1268 10.1084/jem.191.8.1263 10770794
35. JY Cheong SW Cho IL Hwang, et al. 2006 Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-α gene promoter polymorphisms J Gastro Hepatology 21 1163 1169 10.1111/j.1440-1746.2006.04304.x
36. Z Ben-Ari E Mor O Papo, et al. 2003 Cytokine gene polymorphisms in patients infected with hepatitis B virus Am J Gastroenterol 98 144 150 10.1111/j.1572-0241.2003.07179.x 12526950
37. T Höhler A Kruger G Gerken, et al. 1998 A tumour necrosis factor-alpha (TNF-α) promoter polymorphism is associated with chronic hepatitis B infection Clin Exp Immunol 111 579 582 10.1046/j.1365-2249.1998. 00534.x 9528902
38. HQ Li Z Li Y Liu, et al. 2006 Association of-238G/A and -857C/T polymorphisms of tumor necrosis factor-alpha gene promoter region with outcomes of hepatitis B virus infection Biomed Environ Sci 19 2 133 136 16827185
39. HQ Li Z Li Y Liu 2005 Association of polymorphism of tumor necrosis factor-alpha gene promoter region with outcome of hepatitis B virus infection World J Gastroenterol 11 33 5213 5217 16127755
40. YJ Kim HS Lee JH Yoon, et al. 2003 Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection Hum Mol Genet 12 19 2541 2546 10.1093/hmg/ddg262 12915457
41. T Du XH Guo XL Zhu, et al. 2006 Association of TNF-alpha promoter polymorphisms with the outcomes of hepatitis B virus infection in Chinese Han population J Viral Hepat 13 9 618 624 10.1111/j.1365-2893.2006.00731.x 16907849
42. JWS Fang WW Shen A Meager, et al. 1996 Activations of the tumor necrosis factor-α system in the liver in chronic hepatitis B virus infection Am J Gastroenterol 91 748 753 8677942
43. B Rehermann 2000 Intrahepatic T cells in hepatitis B: viral control versus liver cell injury J Exp Med 191 1263 1268 10.1084/jem.191.8.1263 10770794
44. F Su RJ Schneider 1997 Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor α Proc Natl Acad Sci USA 94 8744 8749 10.1073/pnas.94.16.8744 9238048
45. R Thimme S Wieland C Steiger, et al. 2003 CD8+ T cells mediate viral clearance and disease pathogenesis during aucte hepatitis B virus infection J Virol 77 68 76 10.1128/JVI.77.1.68-76.2003 12477811
46. TM Block H Guo JT Guo 2007 Molecular virology of hepatitis B virus for clinicians Clin Liver Dis 11 685 706 10.1016/j.cld.2007.08.002 17981225
47. J Petersen M Lutgehetmann T Volz, et al. 2007 What is the role of cccDNA in chronic HBV infection? Impact on HBV therapy Hepatol Rev 4 9 13
48. W Gao J Hu 2007 Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein J Virol 81 6164 6174 10.1128/JVI.02721-06 17409153
49. JJ Sung ML Wong S Bowden 2005 Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy Gastroenterol 128 1890 1897 10.1053/j.gastro.2005.03.009
50. F Zoulim 2005 New insight on HBV persistence from the study of intrahepatic viral cccDNA J Hepatol 42 302 308 10.1016/j.jhep.2004.12.015 15710212
51. MK Maini C Boni CK Lee, et al. 2000 The role of virus-specific CD8+ cells in liver damage and viral control during persistent hepatitis B virus infection J Exp Med 191 1269 1281 10.1084/jem.191.8.1269 10770795
52. MJ Hussain JY Lau R Williams, et al. 1994 Hepatic expression of tumour necrosis factor-alpha in chronic hepatitis B virus infection J Clin Pathol 47 12 1112 1115 10.1136/jcp.47.12.1112 7876386
53. D Ganem AM Prince 2004 Hepatitis B virus infection-natural history and clinical consequences N Engl J Med 350 1118 1129 10.1056/NEJMra031087 15014185
54. JE Jeng JF Tsai LY Chuang, et al. 2007 Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma Neoplasia 9 11 987 992 10.1593/neo.07781 18030367
55. Remicade website (2010) Centocor. http://www.remicade.com/remicade/ global/index.html. Accessed 7 April 2010
56. D Tracey L Klareskog EH Sasso, et al. 2008 Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacol Ther 117 244 279 10.1016/j.pharmthera.2007.10.001 18155297
57. DE Furst O Beenhouwer 2006 Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection Semin Arthritis Rheum 36 3 159 167 10.1016/j.semarthrit.2006.02.001 16884970
58. AL Weaver 2003 Differentiating the new rheumatoid arthritis biologic therapies J Clin Rheumatol 9 2 99 114 10.1097/01.RHU.0000062513.64012.1d 17041440
59. NJ Olsen CM Stein 2004 New drugs for rheumatoid arthritis N Engl J Med 350 21 2167 2179 10.1056/NEJMra032906 15152062
60. U.S. Food and Drug Administration Center for Drug Evaluation and Research (2004) Drugs@FDA: Infliximab Label Information. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2004/103772-5077-lbl.pdf. Accessed 8 August 2009
61. T Bourne G Fossati A Nesbitt 2008 A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn's disease Biodrugs 22 5 331 337 10.2165/00063030-200822050-00005 18778114
62. H Mitoma T Horiuchi H Tsukamoto, et al. 2008 Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor α-expressing cells: comparison among infliximab, etanercept, and adalimumab Arthritis Rheum 58 5 1248 1257 10.1002/art.23447 18438840
63. DL Scott A Cope 2009 New tumor necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice? Ann Rheum Dis 68 6 767 769 10.1136/ard.2008.105940 19435722
64. G Fossati A Nesbitt 2005 In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870): 807 Am J Gastro 100 supp 1 S299
65. OY Saliu C Sofer D Stein, et al. 2006 Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity J Infect Dis 194 486 492 10.1086/505430 16845632
66. F Tubach D Salmon P Ravaud, et al. 2009 Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy Arthritis Rheum 60 7 1884 1894 10.1002/art.24632 19565495
67. P Suwannalai P Auethavekiat U Udomsubpayakul, et al. 2009 The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital Int J Rheum Dis 12 2 118 124 10.1111/j.1756-185X.2009.01393.x 20374328
68. T Takeuchi Y Tatsuki Y Nogami, et al. 2008 Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis Ann Rheum Dis 67 2 189 194 10.1136/ard.2007.072967 17644554
69. T Koike M Harigai S Inokuma, et al. 2009 Postmarketing surveillance of the safety and effectiveness of etanercept in Japan J Rheum 36 5 898 906 10.3899/jrheum.080791 19332630
70. U.S. Food and Drug Administration Center for Drug Evaluation and Research (1999) Drugs@FDA: Infliximab Product Approval Information. < http://www.accessdata.fda.gov/drugsatfda-docs/appletter/1999/inflcen111099L.htm. Accessed 17 March 2010
71. U.S. Food and Drug Administration Center for Drug Evaluation and Research (2002) Drugs@FDA: Etanercept Product Approval Information-Licensing Action. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2002/etanimm011502L.htm. Accessed 17 March 2010
72. DM Nathan PW Angus PR Gibson 2006 Hepatitis B and C virus infections and anti-tumor necrosis factor-α therapy: guidelines for clinical approach J Gastroenterol Hepatol 21 1366 1371 10.1111/j.1440-1746.2006.04559.x 16911678
73. TJ Liang 2009 Hepatitis B: the virus and disease Hepatology 49 5 Suppl S13 S21 10.1002/hep.22881 19399811
74. KG Saag GG Teng NM Patkar, et al. 2008 American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum 59 6 762 784 10.1002/art.23721 18512708
75. J Ledingham C Deighton 2005 Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001) Rheumatology 44 2 157 163 10.1093/rheumatology/keh464 15637039
76. British Society of Rheumatology. "BSR Guidelines." http://www.rheumatology.org.uk/guidelines/. Accessed 15 August 2009
77. GR Lichtenstein MT Abreu R Cohen, et al. 2006 American Gastroenterologic Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease Gastroenterology 130 935 939 10.1053/j.gastro.2006.01.047 16530531
78. MJ Carter AJ Lobo SPL Travis 2004 Guidelines for the management of inflammatory bowel disease in adults Gut 53 Supp V v1 v16 10.1136/gut.2004. 043372 15306569
79. SB Desai DE Furst 2006 Problems encountered during anti-tumor necrosis factor therapy Best Prac & Res Clin Rheum 20 4 757 790 10.1016/j.berh.2006. 06.002
80. D Vassilopoulos LH Calabrese 2007 Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections Curr Opin Rheumatol 19 619 625 10.1097/BOR. 0b013e3282f05b63 17917544
81. M Marignani MC Cox G Delle Fave 2009 Hepatitis B virus infection N Engl J Med 360 3 304 306 19148965
82. H Tilg A Kaser AR Moschen 2006 How to modulate inflammatory cytokines in liver disease Liver Int 26 1029 1039 10.1111/j.1478-3231.2006.01339.x 17032402
83. LH Calabrese NN Zein D Vassilopoulos 2006 Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies Ann Rheum Dis 65 983 989 10.1136/ard.2005.043257 16627542
84. JY Cheong SW Cho IL Hwang, et al. 2006 Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-α gene promoter polymorphisms J Gastro Hepatology 21 1163 1169 10.1111/j.1440-1746.2006.04304.x
85. CL Thio DL Thomas M Carrington 2000 Chronic viral hepatitis and the human genome Hepatology 31 819 827 10.1053/he.2000.4316 10733534
86. HI Yang SN Lu YF Liaw, et al. 2002 Hepatitis B e antigen and the risk of hepatocellular carcinoma N Engl J Med 347 3 168 174 10.1056/NEJMoa013215 12124405